Medpace (NASDAQ:MEDP) CEO August Troendle Sells 650 Shares

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 650 shares of the stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $620.27, for a total value of $403,175.50. Following the completion of the sale, the chief executive officer owned 539,894 shares in the company, valued at approximately $334,880,051.38. This trade represents a 0.12% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Medpace Price Performance

MEDP stock opened at $593.99 on Tuesday. Medpace Holdings, Inc. has a one year low of $373.00 and a one year high of $677.90. The stock has a market cap of $16.58 billion, a price-to-earnings ratio of 34.82, a price-to-earnings-growth ratio of 2.68 and a beta of 1.15. The company has a fifty day moving average price of $568.10 and a two-hundred day moving average price of $495.34.

Medpace (NASDAQ:MEDP) last posted its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. During the same quarter last year, the company posted $3.10 EPS. Medpace’s quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Research analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Institutional Investors Weigh In On Medpace

A number of hedge funds have recently made changes to their positions in the stock. Johnson Financial Group Inc. acquired a new position in Medpace during the 2nd quarter worth approximately $27,000. Geneos Wealth Management Inc. boosted its position in Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares in the last quarter. Elyxium Wealth LLC bought a new stake in shares of Medpace during the fourth quarter worth $30,000. Jones Financial Companies Lllp bought a new stake in shares of Medpace during the second quarter worth $30,000. Finally, Allied Private Wealth LLC acquired a new position in shares of Medpace during the second quarter worth $31,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have commented on MEDP. Royal Bank Of Canada upped their price objective on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Jefferies Financial Group lowered shares of Medpace from a “buy” rating to a “hold” rating and raised their price target for the stock from $490.00 to $515.00 in a research report on Tuesday, July 7th. TD Cowen lifted their price objective on shares of Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Weiss Ratings raised shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th. Finally, Leerink Partners set a $620.00 price target on shares of Medpace in a research report on Thursday, July 23rd. Three research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $584.18.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.